Cerecin is focused on developing innovative treatments for neurological diseases by targeting metabolic dysfunctions in the brain. Their core technology revolves around synthesizing and formulating ketone precursors, particularly tricaprilin, which is designed to induce ketosis. This process is believed to provide an alternative energy source for brain cells, especially in conditions like Alzheimer’s disease, migraines, and pediatric epilepsy. Cerecin's approach leverages their expertise in lipid-based therapeutics and employs a proprietary method of synthesis to create ultrapure tricaprilin, which meets stringent safety standards. Their novel Lipid in NanoEmulsion (LINE) technology enhances the bioavailability of these compounds, potentially improving therapeutic outcomes.

The company’s pipeline includes investigational drugs such as CER-0001, aimed at treating mild to moderate Alzheimer’s disease, and CER-022, a radiolabeled ketone body for diagnosing neurological conditions related to ketone metabolism. Cerecin's research emphasizes the importance of ketosis in managing neurological disorders, as it may help mitigate energy deficits and oxidative stress in compromised neuronal cells. By exploring the metabolic underpinnings of these conditions, Cerecin aims to address significant unmet medical needs and improve the quality of life for patients suffering from various neurological disorders.

Singapore

Cerecin is a global healthcare company with almost 20 years of innovation and leadership in brain health.

At Cerecin we think differently. We develop novel evidence-based solutions that help people; pharmaceuticals, medical foods, diagnostics, medical devices and e-health products. These solutions target conditions ranging from memory impairment to some of the most devastating neurological diseases.

Cerecin

Company Details